Send to

Choose Destination
J Cell Physiol. 2012 Jul;227(7):2818-21. doi: 10.1002/jcp.23038.

PI3K: a potential therapeutic target for cancer.

Author information

Department of Gastroenterology, School of Medicine, Xin Hua Hospital, Shanghai Jiao Tong University, Shanghai, China.


Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival, and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center